Pay in 4 interest-free payments of $6.80 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
Best for isolated tendon or ligament work, gut-lining repair, or specific injury recovery
Treatment plans must align with lab results, medical history, and response to therapy
population but evades most practitioners radar
2027 Capturing the impact of Facioscapulohumeral Muscular Dystrophy (FSHD) on Health-related Quality of Life (HRQoL): a systematic review of the reliability and validity of existing self-report instruments using COSMIN Jill Carlton 1 , Philip Powell 1 , S Frances 1 , Claire Williams 1 , Anthea Sutton 1 , Jonathan Street 1 , Channa Hewamadduma 1 , Jill Carlton 1 1 University of Sheffield, Sheffield, UK Journal of Patient-Reported Outcomes 2026 , 10(Suppl 1) :2027 Aims Facioscapulohumeral muscular dystrophy (FSHD) is a rare genetic muscle wasting condition causing progressive weakness
This story first appeared on MM+M.
US$ 26.69
US$ 24.05
US$ 22.47
